MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The effect of walking speed on postural stability in Parkinson’s disease fallers

    M.H. Cole, M. Sweeney, Z.J. Conway, T.D. Blackmore, P.A. Silburn (Virginia, Australia)

    Objective: This cross-sectional study aimed to evaluate the effect of imposed faster and slower walking speeds on gait rhythmicity in people with Parkinson's disease (PD)…
  • 2016 International Congress

    Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists

    S. Xu, J. Liu, X. Yang, Y. Qian, Q. Xiao (Shanghai, People's Republic of China)

    Objective: To investigate the association between dopamine receptor D types 2(DRD2) (CA)n and types 3 (DRD3) Ser9Gly polymorphisms and the risk of Parkinson's disease (PD),…
  • 2016 International Congress

    Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

    M. Senek, D. Nyholm (Uppsala, Sweden)

    Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • 2016 International Congress

    Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC

    A.E. Halpern, L.O. Ramig, K. Freeman, J.L. Spielman (Denver, CO, USA)

    Objective: To evaluate the functional impact of LSVT LOUD and LSVT ARTIC on voice and communication in individuals with Parkinson's disease (PD) immediately post and…
  • 2016 International Congress

    Preclinical evaluation of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias: Is it a ‘chemical’ DBS?

    T. Falk, M.J. Bartlett, T. Ye, L.B. Lazarus, M.L. Heien, S.L. Cowen, S.J. Sherman (Tucson, AZ, USA)

    Objective: To evaluate mechanism of long-term activity of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias (LID). Background: Ketamine is an anesthetic that, when administered as…
  • 2016 International Congress

    Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry

    V. Felix Saunders, K. Li, S. Luo, T. Simuni (Chicago, IL, USA)

    Objective: To evaluate baseline predictors and longitudinal impact of anticholinergics use in Parkinson's disease (PD). Background: Anticholinergics have beneficial effect on tremor in PD but…
  • 2016 International Congress

    ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump

    R. Shaltiel-Karyo, Y. Tsarfati, E. Zawoznik, I. Weinstock, M. Nemas, A. Rubinski, Y.S. Schiffenbauer, A. Nyska, O. Yacoby-Zeevi (Rehovot, Israel)

    Objective: To characterize the local safety and PK of a novel apomorphine formulation, ND0701, in comparison to a commercially available apomorphine–HCl solution. Background: Apomorphine is…
  • 2016 International Congress

    The Luxembourg Parkinson’s study: Integrating the Lewy body composite risk score into a longitudinal study

    M. Kerschenmeyer, P. Kolber, G. Hipp, K. Roomp, S.K. Mosch, A. Schweicher, L. Longhino, M. Falz, V.P. Satagopam, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schreiner, R. Krüger (Belval, Luxembourg)

    Objective: To validate the LBCRS in a longitudinal national cohort study. The Lewy Body Composite Risk ScorePlease rate the following physical findings being present or…
  • 2016 International Congress

    Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease

    A.Y. Son, M.C. Biagioni, E. Pirraglia, A. DiRocco (New York, NY, USA)

    Objective: To observe changes in handwriting following administration of repetitive transcranial magnetic stimulation (rTMS) over pre-motor cortex (pre-MC) in patients with PD. Background: Patients with…
  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley